First Header Logo Second Header Logo

Jill Ohar MD

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine, Pulmonary, Critical Care, Allergy and Immunologic Diseases
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cheung M, Kadariya Y, Sementino E, Hall MJ, Cozzi I, Ascoli V, Ohar JA, Testa JR. Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Hum Mol Genet. 2021 May 18. PMID: 34008015.
      Citations:    
    2. Tashkin DP, Ohar JA, Koltun A, Allan R, Ward JK. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. Pulm Med. 2021; 2021:8881895. PMID: 33815843.
      Citations:    
    3. Mahler DA, Ohar JA, Ferguson GT, Donohue JF. Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally Important. Am J Respir Crit Care Med. 2020 11 15; 202(10):1482. PMID: 32791005.
      Citations:    
    4. Ohar JA, Bauer A, Sharma S, Sanjar S. In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®. Pulm Ther. 2020 Dec; 6(2):289-301. PMID: 32809156.
      Citations:    
    5. Macrea M, Oczkowski S, Rochwerg B, Branson RD, Celli B, Coleman JM, Hess DR, Knight SL, Ohar JA, Orr JE, Piper AJ, Punjabi NM, Rahangdale S, Wijkstra PJ, Yim-Yeh S, Drummond MB, Owens RL. Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 08 15; 202(4):e74-e87. PMID: 32795139.
      Citations:    
    6. Ohar JA, Ozol-Godfrey A, Goodin T, Sanjar S. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. Int J Chron Obstruct Pulmon Dis. 2020; 15:995-1004. PMID: 32440111.
      Citations:    
    7. Barnes CN, Mahler DA, Ohar JA, Lombardi DA, Crater GD. Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different Inhalers. Chest. 2020 10; 158(4):1413-1419. PMID: 32343967.
      Citations:    
    8. Mahler DA, Ohar JA, Barnes CN, Moran EJ, Pendyala S, Crater GD. Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate. Chronic Obstr Pulm Dis. 2019 Oct 23; 6(4). PMID: 31647854.
      Citations:    
    9. Ohar JA, Donohue JF, Spangenthal S. The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review. Chronic Obstr Pulm Dis. 2019 Oct 23; 6(4). PMID: 31647856.
      Citations:    
    10. Ohar JA, Sharma S, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sanjar S. Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies. COPD. 2019 04; 16(2):133-139. PMID: 31242792.
      Citations:    
    11. Namen AM, Forest DJ, Ahmad ZN, Chatterjee AB, Saha AK, Kumar S, Edwards AF, Ohar JA, Kassis N, Sy AO, Peters SP, Haponik EF. Preoperative Sleep Questionnaires Identify Medical Emergency Team Activation in Older Adults. J Am Med Dir Assoc. 2019 10; 20(10):1340-1343.e2. PMID: 31201101.
      Citations:    
    12. Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:585-595. PMID: 30880948.
      Citations:    
    13. Ohar JA, Bowling A, Goodin T, Price B, Ozol-Godfrey A, Sharma S, Sanjar S. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies. Int J Chron Obstruct Pulmon Dis. 2019; 14:461-470. PMID: 30863047.
      Citations:    
    14. Pleasants RA, Heidari K, Ohar J, Donohue JF, Lugogo N, Richard CL, Kanotra S, Mannino DM, Kraft M, Liao W, Strange C. Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease. Healthcare (Basel). 2019 Jan 18; 7(1). PMID: 30669305.
      Citations:    
    15. Ohar J, Tosiello R, Goodin T, Sanjar S. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. Int J Chron Obstruct Pulmon Dis. 2019; 14:27-37. PMID: 30587959.
      Citations:    
    16. Ohar J, Putcha N, Bradshaw M. Asthma-Chronic Obstructive Pulmonary Disease Overlap: Diagnostic and Management Challenges. J Fam Pract. 2018 10; 67(10 Suppl):S46-S51. PMID: 30423011.
      Citations:    
    17. Braman SS, Carlin BW, Hanania NA, Mahler DA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Dhand R. Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. Respir Care. 2018 07; 63(7):840-848. PMID: 29717099.
      Citations:    
    18. Hanania NA, Braman S, Adams SG, Adewuya R, Ari A, Brooks J, Mahler DA, Ohar JA, Peters J, Sanjar S. The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers. Chronic Obstr Pulm Dis. 2018 Apr 01; 5(2):111-123. PMID: 30374449.
      Citations:    
    19. Loh CH, Genese FA, Kannan KK, Lovings TM, Peters SP, Ohar JA. Spirometry in Hospitalized Patients with Acute Exacerbation of COPD Accurately Predicts Post Discharge Airflow Obstruction. Chronic Obstr Pulm Dis. 2018 Apr 01; 5(2):124-133. PMID: 30374450.
      Citations:    
    20. Dhand R, Mahler DA, Carlin BW, Hanania NA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Braman SS. Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. Respir Care. 2018 07; 63(7):833-839. PMID: 29559537.
      Citations:    
    21. Ghosh S, Ohar JA, Drummond MB. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers. J Aerosol Med Pulm Drug Deliv. 2017 Dec; 30(6):381-387. PMID: 28933581.
      Citations:    
    22. Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions. Ann Am Thorac Soc. 2017 Aug; 14(8):1305-1311. PMID: 28406710.
      Citations:    
    23. Loh CH, Ohar JA. Personalization of Device Therapy - Prime Time for Peak Inspiratory Flow Rate. Chronic Obstr Pulm Dis. 2017 Jul 14; 4(3):172-176. PMID: 28848928.
      Citations:    
    24. Ohar JA. Medicare Bundled Payments for Care Improvement Initiative for Chronic Obstructive Pulmonary Disease Readmissions: A Negative Study That Has Positive Implications. Ann Am Thorac Soc. 2017 05; 14(5):617-618. PMID: 28459621.
      Citations:    
    25. Bonnecaze AK, Willeford WG, Lichstein P, Ohar J. Acute Cytomegalovirus (CMV) Infection Associated with Hemophagocytic Lymphohistiocytosis (HLH) in an Immunocompetent Host Meeting All Eight HLH 2004 Diagnostic Criteria. Cureus. 2017 Mar 02; 9(3):e1070. PMID: 28409071.
      Citations:    
    26. Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin DP. Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. Chronic Obstr Pulm Dis. 2016 Nov 15; 4(1):7-20. PMID: 28848907.
      Citations:    
    27. Ohar JA, Yawn BP, Ruppel GL, Donohue JF. A retrospective study of two populations to test a simple rule for spirometry. BMC Fam Pract. 2016 06 04; 17:65. PMID: 27259805.
      Citations:    
    28. Kumbhare S, Pleasants R, Ohar JA, Strange C. Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. Ann Am Thorac Soc. 2016 06; 13(6):803-10. PMID: 26974689.
      Citations:    
    29. Cohen JS, Miles MC, Donohue JF, Ohar JA. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis. 2016; 11:785-97. PMID: 27143870.
      Citations:    
    30. Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, Liu Y, Strange C. Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. J Asthma. 2016 09; 53(7):720-31. PMID: 27043854.
      Citations:    
    31. Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Res. 2016 Jan 15; 76(2):206-15. PMID: 26719535.
      Citations:    
    32. Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett. 2015 Dec 28; 369(2):261-5. PMID: 26409435.
      Citations:    
    33. Pleasants RA, Heidari K, Wheaton AG, Ohar JA, Strange C, Croft JB, Liao W, Mannino DM, Kraft M. Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. COPD. 2015; 12(6):680-9. PMID: 26367193.
      Citations:    
    34. Ohar JA. Risks May Not Be Reasons for COPD Readmissions. Ann Am Thorac Soc. 2015 Sep; 12(9):1259-60. PMID: 26372799.
      Citations:    
    35. Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, Ohar JA, Kraft M, Mannino DM, Strange C. Smoking duration, respiratory symptoms, and COPD in adults aged =45 years with a smoking history. Int J Chron Obstruct Pulmon Dis. 2015; 10:1409-16. PMID: 26229460.
      Citations:    
    36. Liu Y, Pleasants RA, Croft JB, Lugogo N, Ohar J, Heidari K, Strange C, Wheaton AG, Mannino DM, Kraft M. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir Med. 2015 Jul; 109(7):851-9. PMID: 26006753.
      Citations:    
    37. Davidson JF, Donohue JF, Ohar JA. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines. Expert Opin Drug Saf. 2015 Feb; 14(2):317-24. PMID: 25598422.
      Citations:    
    38. Faig J, Howard S, Levine EA, Casselman G, Hesdorffer M, Ohar JA. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015 Feb; 8(1):35-9. PMID: 25749175.
      Citations:    
    39. Loh CH, Donohue JF, Ohar JA. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015 Mar; 14(3):463-72. PMID: 25563342.
      Citations:    
    40. Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT. Fluticasone propionate/salmeterol 250/50 µg versus salmeterol 50 µg after chronic obstructive pulmonary disease exacerbation. Respir Res. 2014 Sep 24; 15:105. PMID: 25248764.
      Citations:    
    41. Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Mannino DM, Donohue JF, Herrick HL. Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD. 2014 Jun; 11(3):256-66. PMID: 24152212.
      Citations:    
    42. Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? Ther Adv Respir Dis. 2013 Apr; 7(2):81-6. PMID: 23147985.
      Citations:    
    43. Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs. 2012 Feb 12; 72(3):301-8. PMID: 22316346.
      Citations:    
    44. Ohar J, Fromer L, Donohue JF. Reconsidering sex-based stereotypes of COPD. Prim Care Respir J. 2011 Dec; 20(4):370-8. PMID: 21922124.
      Citations:    
    45. Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med. 2010 Jun; 31(3):321-33. PMID: 20496301.
      Citations:    
    46. Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER. Do symptoms predict COPD in smokers? Chest. 2010 Jun; 137(6):1345-53. PMID: 20363841.
      Citations:    
    47. Brown DW, Pleasants R, Ohar JA, Kraft M, Donohue JF, Mannino DM, Liao W, Herrick H. Health-related quality of life and chronic obstructive pulmonary disease in North Carolina. N Am J Med Sci. 2010 Feb; 2(2):60-5. PMID: 22624116.
      Citations:    
    48. Ohar JA, Hamilton RF, Zheng S, Sadeghnejad A, Sterling DA, Xu J, Meyers DA, Bleecker ER, Holian A. COPD is associated with a macrophage scavenger receptor-1 gene sequence variation. Chest. 2010 May; 137(5):1098-107. PMID: 20081102.
      Citations:    
    49. Schünemann HJ, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L, Ohar J, McDermott S, Lucas L, Jaeschke R. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med. 2009 Sep 15; 180(6):564-80. PMID: 19734351.
      Citations:    
    50. Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, Bleecker ER. Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res. 2009 Mar 12; 10:21. PMID: 19284602.
      Citations:    
    51. Cazzola M, Hanania NA, Jones PW, Mahler DA, Make B, Ohar J, Rennard S. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48. PMID: 18582796.
      Citations:    
    52. Ampleford EJ, Ohar J. Mesothelioma: you do not have to work for it. Diagn Cytopathol. 2007 Dec; 35(12):774-7. PMID: 18008340.
      Citations:    
    53. Sadeghnejad A, Meyers DA, Bottai M, Sterling DA, Bleecker ER, Ohar JA. IL13 promoter polymorphism 1112C/T modulates the adverse effect of tobacco smoking on lung function. Am J Respir Crit Care Med. 2007 Oct 15; 176(8):748-52. PMID: 17615386.
      Citations:    
    54. Ohar JA, Ampleford EJ, Howard SE, Sterling DA. Identification of a mesothelioma phenotype. Respir Med. 2007 Mar; 101(3):503-9. PMID: 16919927.
      Citations:    
    55. Ohar J, Sterling DA, Bleecker E, Donohue J. Changing patterns in asbestos-induced lung disease. Chest. 2004 Feb; 125(2):744-53. PMID: 14769760.
      Citations:    
    56. Donohue JF, Ohar JA. Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004; 1(3):152-60. PMID: 16113428.
      Citations:    
    57. Cramer SD, Chang BL, Rao A, Hawkins GA, Zheng SL, Wade WN, Cooke RT, Thomas LN, Bleecker ER, Catalona WJ, Sterling DA, Meyers DA, Ohar J, Xu J. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst. 2003 Jul 16; 95(14):1044-53. PMID: 12865450.
      Citations:    
    58. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002 Oct; 32(2):321-5. PMID: 12244320.
      Citations:    
    59. Xu J, Meyers DA, Sterling DA, Zheng SL, Catalona WJ, Cramer SD, Bleecker ER, Ohar J. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. Cancer Epidemiol Biomarkers Prev. 2002 Jul; 11(7):664-9. PMID: 12101115.
      Citations:    
    Ohar's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (214)
    Explore
    _
    Co-Authors (9)
    Explore
    _
    Similar People (51)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _